Abstract Library

#4580 Improving diagnosis of neuroendocrine tumours using large language models

Introduction: Neuroendocrine tumours (NETs) are a heterogeneous group of cancers that can be difficult to diagnose due to their variable clinical presentation and non-specific symptoms. Accurate diagnosis often requires integrating a wide range of clinical, radiological, and pathological information. Large language models (LLMs) have shown promise in processing and understanding complex medical text, making them a valuable tool for improving diagnostic accuracy in oncology.

Conference:

Presenting Author:

Authors: Tang Z, Chen P, Tang J, Li H, Chen Y,

Keywords: Neuroendocrine Tumour (NET), Large Language Model (LLM), Medical Natural Language Processing (NLP), Clinical Decision Support,

#4522 Leveraging large language models for enhanced diagnosis of neuroendocrine tumours

Introduction: Neuroendocrine tumours (NETs) are a heterogeneous group of cancers that are difficult to diagnose due to their variable clinical presentation and non-specific symptoms. Accurate diagnosis often requires integrating a wide range of clinical, radiological, and pathological information. However, clinicians may struggle to synthesise these diverse data sources effectively. Large language models (LLMs) have shown promise in processing and understanding complex medical text, making them a valuable tool for improving diagnostic accuracy in oncology.

Conference:

Presenting Author:

Authors: Tang Z, Tang J, Cheng F, Li H, Chen Y,

Keywords: Neuroendocrine Tumour (NET), Large Language Model (LLM), Medical Natural Language Processing (NLP), Clinical Decision Support,

#4490 Parietal cell-selective Slc26a9 deletion in mice causes gasdermin D mediates mitochondrial damage and pyroptosis, which is the key event to induce autoimmune gastritis

Introduction: Autoimmune gastritis (AIG) is the basis of gastric malignancy, including neuroendocrine tumour (NET) and gastric cancer (GC). We reported that Slc26a9 is highly expressed in parietal cells (PCs), and its deficiency caused GC.

Conference:

Presenting Author: Liu X

Authors: Ji B, Deng Z, Ma Z, Li T, Tuo B,

Keywords: Slc26a9, autoimmune gastritis, Pyroptosis, gastric mucosal immunity remodelling,

#4412 25-years of experience with somatostatin receptor-based therapy in patients with small intestinal neuroendocrine tumours

Introduction: Small intestinal neuroendocrine tumours are well-differentiated and express type 2 somatostatin receptors (SSTR2). Treatment with somatostatin analogues (SSA) (octreotide or lanreotide) has been a cornerstone in controlling tumour growth for 25 years. Peptide Receptor Radionuclide Therapy (PRRT), utilising radiolabelled SSA, was introduced in our institution in May 2009 as primarily 2nd line treatment after progression on SSA. The standard PRRT regimen includes 4 cycles of PRRT (7.4 GBq 177Lu-DOTATATE every eight weeks). Re-treatment protocols remain debated.

Conference:

Presenting Author: Andreassen M

Authors: Slott C, Oturai P, Langer S, Møller S, Hansen C,

Keywords: SSA, PRRT, small intestinal NET,

#4359 Treatment response and survival in 163 metastatic colorectal neuroendocrine carcinomas: A prospective cohort from the Nordic NEC registry

Introduction: Colorectal neuroendocrine carcinoma (CR-NEC) is a rare and aggressive disease. Most cases are metastatic at diagnosis and palliative chemotherapy is the only systemic treatment option.

Conference:

Presenting Author: Morken S

Authors: Morken S, Langer S, Knigge U, Hjortland G, Sundlöv A,

Keywords: neuroendocrine carcinoma, NEC, colorectal, chemotherapy,